In ABO-incompatible (ABOi) kidney transplantation (KT), antibodies can mediate immunological accommodation or immune rejection, but the mechanism by which B cells are induced to produce antibodies with different functions is still unclear. Previous research established an ABOi kidney cell model and identified that haptoglobin (HP) is associated with the activation of lymphocytes. In the present study, the results of a flow cytometric assay demonstrated that HP was expressed by B cells. Moreover, dot-ELISA and ELISA analyses showed that the concentrations of total IgG, blood group B antibody, IgG1, IgG2 and IgG4 were all significantly increased in the cell model. In addition, dot-ELISA and haptoglobin level analyses showed that HP protein expression was significantly increased, while RT-qPCR assay indicated that HP was significantly reduced at the mRNA level. Furthermore, bioinformatics analysis showed that HP could interact with Smad3, and the HP-Smad3 complex was detected in a peripheral blood mononuclear cell (PBMC) protein extract by a dot-ELISA method. This research revealed that HP was involved in the process of B-cell activation by interacting with Smad3, and the results will be helpful to reveal the mechanism of B-cell activation in ABOi-KT.
Introduction
Since the first ABO-incompatible (ABOi) kidney transplantation (KT), was carried out in Japan in 1989 and excellent long-term outcomes were obtained in subsequence surgeries (1) (2) (3) , the number of cases of ABOi-KT have gradually increased worldwide. To avoid graft rejection in ABOi-KT, immunosuppression is usually used to maintain the titre of ABO blood group antibodies at a low level and to inhibit B-cell activation (4) (5) (6) . However, antibody-mediated graft rejection is still one of the major causes of poor outcome in the clinic.
Notably, in various ABOi-KT cases, the ABO blood group antibody returned to baseline levels without antibody-mediated graft rejection. For instance, Makroo et al found that after ABOi-KT the graft survived normally, even though the ABO blood group antibody titre returned to the preoperative level (7) . Snell et al noted that the kidney graft survived normally for three years while the recipient did not receive any B-cell-targeted therapy, such as rituximab (8) . In other words, immunological accommodation occurred in those cases.
Many researchers have found that the process of immunological accommodation is associated with changes in graft antigen and B-cell activation. After ABOi-KT, ABO blood group antigens on the endothelium of the kidney graft were found to be significantly decreased (9) , and soluble ABO blood antigen produced by the transplanted kidney are able to bind to antibodies to reduce antibody-mediated immune reactions (10) , thus the graft antigen may be one of the mechanisms underlying immunological accommodation. On the other hand, in ABOi-KT, B cells could be activated to produce enhancing antibodies (also named blocking antibodies) that bind competitively with ABO blood group antigens thus preventing an immune response (11) . Consequently, ABO blood group antibodies play an important role in the process of immunological accommodation, but the mechanism of B-cell activation to produce antibodies with different functions is still unclear.
Previous research has identified that haptoglobin is associated with the activation of cytokine-induced killer cells (CIKs) (12) , and B cells in peripheral blood mononuclear cells (PBMCs) from blood group A could be activated by HK2 cells carrying blood group B antigen (13) . In the present study, the role of HP in B-cell activation was analyzed by flow cytometry, dot-ELISA and bioinformatics. These results will provide novel insight for further research on immunological accommodation in ABOi-KT conditions.
Materials and methods
Peripheral blood was donated from blood group A volunteers after informed consent. The study was approved by the Animal Welfare and Research Ethics Committee of the Institute of University of South China (Hengyang, Hunan, China).
Cell culture. Peripheral blood mononuclear cells (PBMCs) from donors with blood group A were separated by the Ficoll density gradient method as reported by Huang et al (14) . The HK2 cells (human, non-tumor cells), which carry human blood group B antigen, and PBMCs were divided into three groups: The HK2 group contained HK2 cells, the PBMC group contained PBMCs, and the HK2+PBMC group contained equal quantities of PBMCs and HK2 cells. All groups were cultured with RPMI-1640 medium (Thermo Fisher Scientific, Inc.) and 15% fetal calf serum (FCS; Thermo Fisher Scientific, Inc.) at 37˚C in 5% CO 2 . In addition, previous research identified that B-cell activation is significantly upregulated to the highest level at day 4 (13) . Thus, all of the cells were collected at day 4 for further detection.
Flow cytometric assay. Day 0 PBMCs were collected and divided into two groups: The isotype control group, which was mixed with 5 µl mouse IgG2α FITC-conjugated antibody (BD Biosciences; cat no. 2137834) and 5 µl mouse IgG1 APC-conjugated antibody (BD Biosciences; cat no. 39573); and the target group, which was mixed with 5 µl mouse anti-human CD3 FITC-conjugated antibody (BD Biosciences; cat. no. 4043995) and 5 µl mouse anti-human CD19 APC-conjugated antibody (BD Biosciences; cat. no. 555415). Both groups were incubated at room temperature for 15 min, and then treated with 200 µl Red Blood Cell Lysis Buffer (Solarbio) at room temperature for 10 min, and centrifuged at 150 x g for 10 min. Following resuspension with 1 ml physiological saline and centrifugation at 150 x g for 10 min, the cells were further treated following the instructions of the Cytofix/Cytoperm™ Fixation/Permeabilization Kit (BD Biosciences). In the process, 1 µl rabbit IgG monoclonal antibody (Abcam) was added to the isotype control group, and 2 µl rabbit anti-human HP (BosterBio) was added to the target group, and then the cells were respectively incubated with 1 µl PE-conjugated goat anti-rabbit IgG (4A Biotech Co., Ltd.). Finally, the cells were analyzed by BD FACS Aria II, and at least 100,000 cells were collected per sample.
Extraction of cell proteins and collection of supernatants. In the coculture system, HK2 cells were adhered on the bottom of a culture dish, while lymphocytes exhibited suspended growth. Thus, in the detection time, the lymphocytes were collected with the culture medium after being shaken lightly, and HK2 cells were collected using trypsinization (Solarbio). The supernatants of all groups were collected and centrifuged at 13,000 x g for 10 min and then transferred into clean EP tubes for further experiments. HK2 cells of the HK2 group, PBMCs of the PBMC group and the HK2+PBMC group were collected and then centrifuged at 900 x g for 10 min. The supernatants of all groups were collected and stored at -20˚C and the cells were resuspended in 2 ml physiological saline. Following centrifugation at 900 x g for 10 min, the cell pellet was collected and total protein was extracted using Native lysis Buffer (Solarbio). The total protein concentration was determined by a BCA Protein Assay Kit (Tiangen). HP concentration was detected by a Haptoglobin Kit (Dialab). All cell protein extracts were stored at -20˚C with 0.01 M phenylmethylsulfonyl fluoride (PMSF).
Dot-ELISA analysis.
A polyvinylidene fluoride (PVDF) membrane was activated with methyl alcohol for 15 sec and then soaked in TBS (Solarbio) for 10 min. For maintaining the comparability among different samples, the total protein concentration of culture supernatant was detected. After the PVDF membrane had dried at room temperature, 2 µl (0.5 µg/µl) protein of each sample was respectively applied to the PVDF membrane. Then, the membrane was blocked with blocking buffer (TBS containing 0.05% Tween-20 and 5% skim milk) at room temperature for 1 h. Following 3 washes with TBS for 5 min each, the membrane was incubated with rabbit anti-human HP (dilution 1:200; BosterBio; cat. no. BA3744) or mouse anti-human blood group B antibody (dilution 1:1,000; Abcam; cat. no. 3968) for 1 h at room temperature and rinsed 3 times with TBS for 5 min each time. The PVDF membrane was incubated with goat anti-rabbit IgG-HRP (dilution 1:5,000; Cell Signaling Technology; cat. no. 7074P2) or goat anti-mouse IgG-HRP (dilution 1:3,000; Thermo Fisher Scientific, Inc.; cat. no. 31431) for 40 min at room temperature. Finally, the membrane was rinsed 2 times with TBS for 15 min each. For the expression analysis of IgM and IgG, PVDF membranes were incubated with goat anti-human IgM-HRP (1:3,000; Thermo Fisher Scientific, Inc.; cat. no. 31415) or goat anti-human IgG-HRP (dilution 1:3,000; Thermo Fisher Scientific, Inc.; cat. no. 31410) for 1 h at room temperature and rinsed 2 times with TBS for 15 min each. All samples were dyed with ECL Plus (Solarbio) and analyzed by ChemiDoc XRS+ (Bio-Rad).
In addition, the interaction of HP and Smad3 was also analyzed using this method. In this experiment, rabbit anti-human Smad3 (dilution 1:200; BosterBio; cat. no. BA4559) and mouse anti-human Smad4 (dilution 1:200; BosterBio; cat. no. BM1601) were used as the primary antibodies, and goat anti-rabbit IgG-HRP (dilution 1:5,000; 
Results

Analysis of lymphocytes expressing HP.
To identify the type of lymphocytes that express HP, PBMCs were analyzed by flow cytometry (Fig. 1) . To avoid the influence from the sample, the starting samples of Fig. 1B was the same as those of Fig. 1A in this experiment. The results showed that the percentage of CD3 + T cells was 56.90% without an obvious HP + cell population (Fig. 1A) , and the percentage of CD19 + B cells was 6.73% and that of HP + cells was 0.95% (Fig. 1B) . After statistical analysis, the average percentage of CD19 + HP + cells was calculated to be 1.16%. These results indicated that CD19 + B cells were the lymphocytes that expressed HP.
Expression of blood group B antibody, IgM, total IgG and IgG subclasses. Human blood group antibodies are divide into two major groups: IgM and IgG (15) . Thus, in this study, the expression of IgM, IgG, blood group B antibody and IgG subclasses in cell culture supernatants were detected after co-culture with HK2 cells. Dot-ELISA analysis showed that IgG and blood group B antibody levels were significantly increased 1.63-and 5.28-fold, respectively, and IgM was not significantly altered ( Fig. 2A and B) . Moreover, an ELISA assay showed that IgG1, IgG2 and IgG4 were increased 1.89-, 1.30-and 1.16-fold, respectively, and IgG3 was increased 1.21-fold, which was not statistically significant ( Fig. 2C , Table II ). These results indicated that the B cells were activated to produce antibodies with different biological activities.
Expression of HP at the mRNA and protein levels. As shown in Fig. 3 , the expressed sequence tags (EST) of HP were highly similar to the sequence of human HP (Fig. 3A and B) . After B cells were activated by HK2 cells, HP mRNA was significantly downregulated 14.38-fold ( Fig. 3C and D) . Moreover, dot-ELISA assay revealed that HP was detected in the cell protein extract of the PBMC and HK2+PBMC groups but not in the cell protein extract of the HK2 cells or in the culture supernatant of any of the groups (Fig. 3E ).
In addition, the concentration of HP in the HK2+PBMC group (0.069 mg/ml) was significantly increased 1.34-fold compared with that in the PBMC group (0.052 mg/ml; Fig. 3F ). These results indicated that HP was associated with the activation of B cells.
Analysis of the interaction protein of HP.
To reveal the signaling pathway of HP in B cells, bioinformatics analysis and dot-ELISA were performed. The results showed that of the 24 potential proteins that interacted with HP, Smad3 (4088), which possessed higher indegree and edge betweenness, was selected as the main candidate (Fig. 4A) . The protein-protein interaction network indicated that Smad3 could interact with other SMAD family proteins such as Smad4 (4089, Fig. 4B ). Furthermore, dot-ELISA verified that the HP-Smad3 and Smad4-Smad3 complexes were detected in the cell protein extraction of PBMCs ( Fig. 4C and E) but not the HP-Smad4 complex (Fig. 4D) . These results indicated that Smad3 was the target protein that interacted with HP.
Discussion
The present study found that HP was mainly expressed by B cells and not by T cells (Fig. 1) . The results were similar to studies that demonstrated that HP is an important activator of immune cells (16) (17) (18) . Based on these results, we conjectured that HP plays important roles in B-cell activation.
To analyze the activation of B cells, IgM, IgG and blood group B antibody were detected using Dot-ELISA. The results showed that the antibodies were not detected in the sample from HK2 cells. Meanwhile, B-cell activation was detected by dot-ELISA and ELISA methods. Dot-ELISA showed that IgG and blood group B antibodies were all significantly increased while IgM was not significantly altered ( Fig. 2A  and B) , and ELISA results showed that IgG1, IgG2 and IgG4 were all significantly upregulated (Fig. 2C) . Ig is the main effector molecule of humoral immunity, and its concentration is related to the number of B cells (19) . That is, B cells in the ABOi kidney cell model were activated to produce different functional antibodies. Following these results, the expression of HP was analyzed at the mRNA and protein levels. After the EST sequence of HP was verified to be that of human HP (Fig. 3A and B) , PCR and RT-qPCR analyses showed that HP mRNA was significantly downregulated ( Fig. 3C and D) . In contrast to the change in HP mRNA levels, HP protein was only detected in PBMCs by dot-ELISA (Fig. 3E) , and the concentration was significantly upregulated after HK2 stimulation (Fig. 3F ). As Liu et al reported (20) , the changes in gene expression at the mRNA and protein levels are not always in line. Therefore, the results suggested that HP was closely related to B-cell activation.
In addition, further research was carried out to explore the possible mechanism by which HP is involved in B-cell activation. Bioinformatics analysis found that HP had 24 interaction proteins (Fig. 4A ). Among them, Smad3 (4088) was selected as the most likely interaction protein because of its higher indegree and edge betweenness. Smad3 is associated with the regulation, differentiation and survival of cells because it is a key signal transducer in multiple signalling pathways (21) (22) (23) . One example is the classic TGF-β signaling pathway, in which Smad3 is a major downstream mediator of TGF-β and is phosphorylated by the activated TGF-β receptor (24, 25) . After phosphorylation, Smad3 is directly involved in Ig class switch recombination in B cells, which allows the production of antibodies of different subtypes and subclasses (26, 27) . Most important for this study, the HP-Smad3 complex was detected in the cell protein extract by the Dot-ELISA method (Fig. 4C-E) . To ensure the reliability of the results of Dot-ELISA, multiple negative and positive controls were selected in this study. For example, Smad3 and Smad4 were identified with interaction (28), thus they were selected as positive controls; Bio-informatic analysis showed that there is no interaction between HP and Smad4, thus they were selected as a negative control. In addition, the BSA group was the negative control for the three groups. After comparison of those control groups, we confirmed that the result of HP combined with Smad3 was reliable.
In conclusion, the results of this study indicate that HP is involved in B-cell activation via interaction with Smad3. This research provides novel insight on immunological accommodation in ABOi-KT, and further research will explore whether the HP-Smad3 complex affects B-cell activation via the TGF-β signaling pathway. 
